# Miracles in Sight – FDA Inspection, Sep 18, 2023

Source: https://www.keypedia.com/records/fda_inspections/miracles-in-sight/06b1fc03-2d2e-4d57-9bd2-ddf9b6e7fe34
Source feed: FDA_Inspections

> FDA inspection 1218383 of Miracles in Sight, September 18, 2023. Classification: No Action Indicated (NAI). 7 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1218383
- Company Name: Miracles in Sight
- Inspection Date: 2023-09-18
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Human Cellular, Tissue, and Gene Therapies
- Product Type: Biologics
- Center: Biologics
- Office Name: Center for Biologics Evaluation and Research
- Citation Count: 0

## Related Documents

- FDA Inspection 1264026 - 2025-03-10
- [FDA Inspection 1118762 - 2020-01-30](https://www.keypedia.com/records/fda_inspections/miracles-in-sight/6da13c22-297b-4033-b6a7-8008e24680c8)
- FDA Inspection 1023209 - 2017-08-11
- FDA Inspection 943193 - 2015-09-23
- [FDA Inspection 868748 - 2014-02-26](https://www.keypedia.com/records/fda_inspections/miracles-in-sight/052e3237-e8ba-434d-92f8-3fbf208a6ac6)

## Related Officers

- [Company Rep](https://www.keypedia.com/people/randy-l-clarida/aae3cc15-a908-4489-9299-7542370ad3cd)

Company: https://www.keypedia.com/companies/miracles-in-sight/6c195406-d1b8-4119-b3d0-62fd827430fe

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d